TY - JOUR
AU - van Voorst, Romy J
AU - Schoenmakers, Daphne H
AU - Bonkowsky, Joshua L
AU - Vanderver, Adeline
AU - Krägeloh-Mann, Ingeborg
AU - Bernard, Geneviève
AU - Bertini, Enrico
AU - Fatemi, Ali
AU - Sgobbi, Paulo V
AU - Wolf, Nicole I
AU - Groeschel, Samuel
AU - Tonduti, Davide
AU - Sevin, Caroline
AU - Orthmann-Murphy, Jennifer L
AU - Schöls, Ludger
AU - Salsano, Ettore
AU - Brais, Bernard
AU - Jaffe, Nicole
AU - Ter Horst, Kasper W
AU - Hannema, Sabine E
AU - Hayes, Katherine G
AU - Meyburg, Jochen
AU - van Heerde, Marc
AU - Sbrocchi, Anne Marie
AU - van Spaendonk, Rosalina
AU - Thiffault, Isabelle
AU - Hofsteenge, Geesje H
AU - Sudmeier-Broek, Carolina
AU - Timmer, Corrie
AU - Skwirut, Donna
AU - Buck, Allyson
AU - Hollberg, Bret
AU - Chapleau, Ron
AU - Dekker, Hanka
AU - Campbell, Susan G
AU - Abbink, Truus E M
AU - Leferink, Prisca S
AU - van der Knaap, Marjo S
TI - Consensus-Based Expert Recommendations for Diagnosis and Clinical Management of Vanishing White Matter.
JO - Neurology
VL - 105
IS - 11
SN - 0028-3878
CY - Philadelphia, Pa.
PB - Wolters Kluwer
M1 - DZNE-2025-01269
SP - e214320
PY - 2025
AB - Vanishing white matter (VWM) is a rare disorder, characterized by degeneration of CNS white matter, clinically often exacerbated by stressors such as fever and minor head trauma. VWM is caused by biallelic pathogenic variants in the EIF2B1-5 genes, causing reduced activity of eukaryotic initiation of translation factor 2B, resulting in dysregulation of the integrated stress response (ISR). New scientific insights and increased clinical trials in experimental therapies highlight the need for clinical guidelines to improve and standardize care for patients with VWM worldwide. Standardized care is important for therapy development, as it lessens clinical variability of trial participants at study entry, enabling more sensitive evaluation of treatment outcomes. The aim of this study was to develop expert consensus-based recommendations for diagnosis and management of VWM. A real-time Delphi process with a multidisciplinary expert panel was conducted to formulate consensus-based recommendations. A literature review was performed to determine the strength of available evidence supporting each recommendation. The consensus yielded 43 recommendations on diagnosis, including genetic and MRI criteria, and on clinical management concerning disease progression, acute and long-term care, and preventive strategies. All known pathogenic and likely pathogenic EIF2B1-5 variants were identified from the literature and Amsterdam Leukodystrophy Center laboratory. An overview of these EIF2B1-5 variants was composed to facilitate diagnosis. Clinically used drugs may activate the ISR, posing a risk in VWM, or have no effect on or suppress the ISR, being probably safe in VWM. A second literature search explored the effects of clinically frequently used drugs on the ISR. Drugs were categorized into those likely to activate the ISR, suppress it, and have no likely effects on the ISR. Final judgment was achieved in a consensus meeting of experts. A patient management card was developed with input from clinical experts and patient advocates to provide information on these consensus-based recommendations in lay language and bridge the gap between scientific evidence and expert opinion on one side and the practical needs of clinicians and families on the other side. This study contributes to improving and standardizing VWM care based on scientific and expert insights, while highlighting key areas for future research.
KW - Humans
KW - Leukoencephalopathies: therapy
KW - Leukoencephalopathies: diagnosis
KW - Leukoencephalopathies: genetics
KW - Consensus
KW - Disease Management
KW - Delphi Technique
KW - Eukaryotic Initiation Factor-2B: genetics
KW - Magnetic Resonance Imaging
KW - White Matter: diagnostic imaging
KW - Eukaryotic Initiation Factor-2B (NLM Chemicals)
LB - PUB:(DE-HGF)16
C6 - pmid:41232062
C2 - pmc:PMC12615013
DO - DOI:10.1212/WNL.0000000000214320
UR - https://pub.dzne.de/record/282299
ER -